These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8798176)

  • 1. A nondivergent specification of the mean treatment dose in interstitial brachytherapy.
    Yu Y
    Med Phys; 1996 Jun; 23(6):905-9. PubMed ID: 8798176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry of 192Ir wires for LDR interstitial brachytherapy following the AAPM TG-43 dosimetric formalism.
    Karaiskos P; Papagiannis P; Angelopoulos A; Sakelliou L; Baltas D; Sandilos P; Vlachos L
    Med Phys; 2001 Feb; 28(2):156-66. PubMed ID: 11243338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dosimetric comparison of 169Yb versus 192Ir for HDR prostate brachytherapy.
    Lymperopoulou G; Papagiannis P; Sakelliou L; Milickovic N; Giannouli S; Baltas D
    Med Phys; 2005 Dec; 32(12):3832-42. PubMed ID: 16475783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anisotropy functions for 103Pd, 125I, and 192Ir interstitial brachytherapy sources.
    Nath R; Meigooni AS; Muench P; Melillo A
    Med Phys; 1993; 20(5):1465-73. PubMed ID: 8289730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advances in brachytherapy--focusing on the permanent implant for early prostate carcinoma].
    Hirokawa Y
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2056-61. PubMed ID: 14712765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Size and positioning reproducibility of an 192Ir brachytherapy stepping source.
    Berndt A; Rickey DW; Rathee S; Bews J
    Med Phys; 2000 Jan; 27(1):129-31. PubMed ID: 10659747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-species prostate implant treatment plans incorporating 192Ir and 125I using a Greedy Heuristic based 3D optimization algorithm.
    Chaswal V; Yoo S; Thomadsen BR; Henderson DL
    Med Phys; 2007 Feb; 34(2):436-44. PubMed ID: 17388159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta versus gamma dosimetry close to Ir-192 brachytherapy sources.
    Baltas D; Karaiskos P; Papagiannis P; Sakelliou L; Loeffler E; Zamboglou N
    Med Phys; 2001 Sep; 28(9):1875-82. PubMed ID: 11585218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement and calculation of heterogeneity correction factors for an Ir-192 high dose-rate brachytherapy source behind tungsten alloy and steel shields.
    Kirov AS; Williamson JF; Meigooni AS; Zhu Y
    Med Phys; 1996 Jun; 23(6):911-9. PubMed ID: 8798161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy assessment of the superposition principle for evaluating dose distributions of elongated and curved 103Pd and 192Ir brachytherapy sources.
    Bannon EA; Yang Y; Rivard MJ
    Med Phys; 2011 Jun; 38(6):2957-63. PubMed ID: 21815369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantation guidelines for 169 Yb seed interstitial treatments.
    Piermattei A; Azario L; Montemaggi P
    Phys Med Biol; 1995 Aug; 40(8):1331-8. PubMed ID: 7480116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
    Nickers P; Thissen B; Jansen N; Deneufbourg JM
    Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monte Carlo calculation of dose rate distributions around 192Ir wires.
    Ballester F; Hernández C; Pérez-Calatayud J; Lliso F
    Med Phys; 1997 Aug; 24(8):1221-8. PubMed ID: 9284243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The half-life of high dose rate Ir-192 sources.
    Podgorsak MB; DeWerd LA; Paliwal BR
    Med Phys; 1993; 20(4):1257-9. PubMed ID: 8413038
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of calculated and measured heterogeneity correction factors for 125I, 137Cs, and 192Ir brachytherapy sources near localized heterogeneities.
    Williamson JF; Perera H; Li Z; Lutz WR
    Med Phys; 1993; 20(1):209-22. PubMed ID: 8455503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calculation of mean central dose in interstitial brachytherapy using Delaunay triangulation.
    Astrahan MA; Streeter OE; Jozsef G
    Med Phys; 2001 Jun; 28(6):1016-23. PubMed ID: 11439471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.
    Krishnamurthy D; Weinberg V; Cunha JA; Hsu IC; Pouliot J
    Brachytherapy; 2011; 10(6):461-5. PubMed ID: 21397569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.
    Butler WM; Stewart RR; Merrick GS
    Med Phys; 2009 Mar; 36(3):776-87. PubMed ID: 19378738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Monte Carlo investigation of the dosimetric characteristics of the VariSource 192Ir high dose rate brachytherapy source.
    Karaiskos P; Angelopoulos A; Baras P; Sakelliou L; Sandilos P; Dardoufas K; Vlachos L
    Med Phys; 1999 Aug; 26(8):1498-502. PubMed ID: 10501049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative verification of 192Ir PDR and HDR source structure by pin-hole autoradiography.
    Kirov AS; Meigooni AS; Zhu Y; Valicenti RK; Williamson JF
    Med Phys; 1995 Nov; 22(11 Pt 1):1753-7. PubMed ID: 8587529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.